Drugs / Group ACYW135 Meningococcal Conjugate Vaccine
Group ACYW135 Meningococcal Conjugate Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07505823 | Mar 2026 → Apr 2027 expected | meningitis, meningococcal infection | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07505810 Comparator | Mar 2026 → Apr 2027 expected | meningitis, meningococcal infection | Sinovac Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Group ACYW135 Meningococcal Conjugate Vaccine | “Group ACYW135 Meningococcal Conjugate Vaccine” NCT07505810 ↗1“Group ACYW135 Meningococcal Conjugate Vaccine” NCT07505823 ↗ |
| Modality | Vaccine | “investigational group ACYW135 meningococcal conjugate vaccine” NCT07505810 ↗ |